Anti-CTLA4 monoclonal antibodies: The past and the future in clinical application

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Ascierto, Paolo A ^a   Marincola, Francesco M ^b   Ribas, Antoni ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; FOTEMUSTINE; IPILIMUMAB; MELANOCYTE PROTEIN PMEL 17; TEMOZOLOMIDE; TICILIMUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; IMMUNOPATHOLOGY; LIVER DISEASE; LYMPHOCYTE COUNT; MELANOMA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; DOSE RESPONSE; DRUG ADMINISTRATION; EDITORIAL; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 81055127514     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-196     Document Type: Note

References (22)

1. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-64. 10.1016/S1470-2045(09)70334-1, 20004617.
2. Lin R, Yellin MJ, ILowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy [2008 ASCO Meeting abstract 9063]. J Clin Oncol 2008, 26:9063.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-23. 10.1056/NEJMoa1003466, 20525992.
4. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-26. 10.1056/NEJMoa1104621, 21639810.
5. Di Giacomo AM, Ascierto PA, Fonsatti E, Pittiglio E, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Parmiani G, Maio M. A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial. [2011 ASCO Meeting abstract TPS230]. J Clin Oncol 2011, 29:TPS230.
6. Simeone E, Gentilcore G, Esposito A, Curvietto M, De Rosa P, De Maio E, Pistillo MP, Queirolo P, Mozzillo N, Ascierto PA. Immunological and biological changes and their correlation with Clinical Response and Survival during Ipilimumab in metastatic melanoma Compassionate Use Program [2011 ESMO Meeting abstract 9322]. Eur J Cancer 2011, 47(suppl 1):686.
7. Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE, Arellano ML. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 2009, 32:322-4. 10.1097/CJI.0b013e31819aa40b, 19242368.
8. Ahmad S, Lewis M, Corrie P, Iddawela M. Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J Oncol Pharm Pract 2011, PubMed PMID: 21807763.
9. Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2011, 29:489-98. 10.1007/s10637-009-9376-8, 20082117.
10. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009, 27:1075-81. 10.1200/JCO.2008.19.2435, 19139427.
11. Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010, 16:1042-8. 10.1158/1078-0432.CCR-09-2033, 20086001.
12. Ribas A, Hauschild A, Kefford R, Punt CJ, Haanen JB, Marmol M, Garbe C, Gomez-Navarro J, Pavlov D, Marshall M. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [2008 ASCO Meeting abstract LBA9011]. J Clin Oncol 2008, 26:LBA9011.
13. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010, 21:1712-7. 10.1093/annonc/mdq013, 20147741.
14. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010, 116:1767-75. 10.1002/cncr.24951, 2917065, 20143434.
15. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263-6. 10.1038/16717, 9930702.
16. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008, 105:14987-92. 10.1073/pnas.0806075105, 2567480, 18818309.
17. Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, Usari T, Domchek SM. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 2010, 16:3485-94. 10.1158/1078-0432.CCR-10-0505, 20479064.
18. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010, 16:2861-71. 10.1158/1078-0432.CCR-10-0569, 2919850, 20460488.
19. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011, 71:5445-54. 10.1158/0008-5472.CAN-11-1138, 21708958.
20. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010, 37:473-84. 10.1053/j.seminoncol.2010.09.001, 3008567, 21074063.
21. Hamid O, Chasalow SD, Tsuchihashi Z, Alaparthy S, Galbraith S, Berman D. Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab [2009 ASCO Meeting abstract 9008]. J Clin Oncol 2009, 27:9008.
22. Ascierto PA, Streicher HZ, Sznol M. Melanoma: a model for testing new agents in combination therapies. J Transl Med 2010, 8:38. 10.1186/1479-5876-8-38, 2873374, 20406483.